JAMDA
Volume 8, Issue 6 , Pages 363-377 , July 2007

Pharmacological Treatment of Geriatric Cachexia: Evidence and Safety in Perspective

  • Shing-Shing Yeh, MD, PhD

      Affiliations

    • Northport VAMC, Geriatric division, Northport, NY
    • S.-S.Y. has received unrestricted research grants from Merck, Bristol-Myers Squibb, and Amgen Pharmaceuticals, and consulting fees from PAR Pharmaceuticals.
    • Corresponding Author InformationAddress correspondence to Shing-Shing Yeh, MD, PhD, Northport VAMC, Geriatric Division, Box 111, 79 Middleville Road, Northport, NY 11768.
    • ,
  • Sherri Lovitt, MD

      Affiliations

    • Northport VAMC, Geriatric division, Northport, NY
    • ,
  • Michael W. Schuster, MD

      Affiliations

    • Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY.
    • M.W.S. has been on advisory boards for GTX, Alder Pharmaceuticals, Bristol-Myers, PAR and Amgen Pharmaceuticals, and has received research funding and lecture honoraria from Amgen and Par Pharmaceuticals.

References 

  1. Payette H, Coulombe C, Boutier V, Gray-Donald K. Nutrition risk factors for institutionalization in a free-living functionally dependent elderly population. J Clin Epidemiol. 2000;53:579–587
  2. Keller HH, Ostbye T. Body Mass Index (BMI), BMI change and mortality in community-dwelling seniors without dementia. J Nutr Health Aging. 2005;9:316–320
  3. Sullivan DH, Liu L, Roberson PK, Bopp MM, Rees JC. Body weight change and mortality in a cohort of elderly patients recently discharged from the hospital. J Am Geriatr Soc. 2004;52:1696–1701
  4. Morley JE. Is weight loss harmful to older men?. Aging Male. 2006;9:135–136
  5. Sullivan DH, Morley JE, Johnson LE, et al. The GAIN (Geriatric Anorexia Nutrition) registry: the impact of appetite and weight on mortality in a long-term care population. J Nutr Health Aging. 2002;6:275–281
  6. Sullivan DH, Johnson LE, Bopp MM, Roberson PK. Prognostic significance of monthly weight fluctuations among older nursing home residents. J Gerontol A Biol Sci Med Sci. 2004;59:M633–M639
  7. Ferrini MT, Waitzberg DL, Pasternak J, Coppini LZ, da Silva Mde L, Gama-Rodrigues J. [Effect of nutritional support on survival of AIDS-IV C patients]. Rev Hosp Clin Fac Med Sao Paulo. 1993;48:161–166
  8. Crocker KS. Gastrointestinal manifestations of the acquired immunodeficiency syndrome. Nurs Clin North Am. 1989;24:395–406
  9. Argiles JM. Cancer-associated malnutrition. Eur J Oncol Nurs. 2005;9(Suppl 2):S39–S50
  10. Morley JE, Kraenzle D. Causes of weight loss in a community nursing home. J Am Geriatr Soc. 1994;42:583–585
  11. Robbins LJ. Evaluation of weight loss in the elderly. Geriatrics. 1989;44:31–347
  12. Rolls BJ, Dimeo KA, Shide DJ. Age-related impairments in the regulation of food intake. Am J Clin Nutr. 1995;62:923–931
  13. Roberts SB, Fuss P, Dallal GE, et al. Effects of age on energy expenditure and substrate oxidation during experimental overfeeding in healthy men. J Gerontol A Biol Sci Med Sci. 1996;51:B148–B157
  14. Roberts SB, Fuss P, Heyman MB, et al. Control of food intake in older men. JAMA. 1994;272:1601–1606
  15. Roberts SB. Abnormalities of energy expenditure and the development of obesity. Obes Res. 1995;3(Suppl 2):155s–163s
  16. Das SK, Moriguti JC, McCrory MA, et al. An underfeeding study in healthy men and women provides further evidence of impaired regulation of energy expenditure in old age. J Nutr. 2001;131:1833–1838
  17. Moriguti JC, Das SK, Saltzman E, et al. Effects of a 6-week hypocaloric diet on changes in body composition, hunger, and subsequent weight regain in healthy young and older adults. J Gerontol A Biol Sci Med Sci. 2000;55:B580–B587
  18. Saltzman E, Roberts SB. Effects of energy imbalance on energy expenditure and respiratory quotient in young and older men: a summary of data from two metabolic studies. Aging (Milano). 1996;8:370–378
  19. Wilson MM, Purushothaman R, Morley JE. Effect of liquid dietary supplements on energy intake in the elderly. Am J Clin Nutr. 2002;75:944–947
  20. McCrory MA, Fuss PJ, McCallum JE, et al. Dietary variety within food groups: association with energy intake and body fatness in men and women. Am J Clin Nutr. 1999;69:440–447
  21. Schiffman SS. Taste and smell losses in normal aging and disease. JAMA. 1997;278:1357–1362
  22. Schiffman SS, Warwick ZS. Effect of flavor enhancement of foods for the elderly on nutritional status: Food intake, biochemical indices, and anthropometric measures. Physiol Behav. 1993;53:395–402
  23. Rolls BJ, Rowe EA, Rolls ET. How sensory properties of foods affect human feeding behavior. Physiol Behav. 1982;29:409–417
  24. White HK, McConnell ES, Bales CW, Kuchibhatla M. A 6-month observational study of the relationship between weight loss and behavioral symptoms in institutionalized Alzheimer’s disease subjects. J Am Med Dir Assoc. 2004;5:89–97
  25. Simmons SF, Osterweil D, Schnelle JF. Improving food intake in nursing home residents with feeding assistance: a staffing analysis. J Gerontol A Biol Sci Med Sci. 2001;56:M790–M794
  26. Abitbol V, Selinger-Leneman H, Gallais Y, et al. [Percutaneous endoscopic gastrostomy in elderly patients. A prospective study in a geriatric hospital]. Gastroenterol Clin Biol. 2002;26:448–453
  27. Mitchell SL, Tetroe JM. Survival after percutaneous endoscopic gastrostomy placement in older persons. J Gerontol A Biol Sci Med Sci. 2000;55:M735–M739
  28. Murphy LM, Lipman TO. Percutaneous endoscopic gastrostomy does not prolong survival in patients with dementia. Arch Intern Med. 2003;163:1351–1353
  29. Tokuda Y, Koketsu H. High mortality in hospitalized elderly patients with feeding tube placement. Intern Med. 2002;41:613–616
  30. Crary MA, Groher ME. Reinstituting oral feeding in tube-fed adult patients with dysphagia. Nutr Clin Pract. 2006;21:576–586
  31. Gomez Ramos MJ, Saturno Hernandez PJ. [Parenteral nutrition in a general hospital: quality criteria and factors associated with compliance]. Med Clin (Barc). 2002;119:686–689
  32. Shintani S, Fumimura Y, Shiigai T, et al. [Feeding methods for long-term bedridden patients with dysphagia under home health care—percutaneous endoscopic gastrostomy (PEG) and intravenous hyperalimentation (IVH)]. Gan To Kagaku Ryoho. 2001;28(Suppl 1):61–64
  33. Marra AR, Opilla M, Edmond MB, Kirby DF. Epidemiology of bloodstream infections in patients receiving long-term total parenteral nutrition. J Clin Gastroenterol. 2007;41:19–28
  34. Thomas DR, Zdrodowski CD, Wilson MM, Conright KC, Diebold M, Morley JE. A prospective, randomized clinical study of adjunctive peripheral parenteral nutrition in adult subacute care patients. J Nutr Health Aging. 2005;9:321–325
  35. Kotler DP, Grunfeld C. Pathophysiology and treatment of the AIDS wasting syndrome. AIDS Clin Rev. 1995;229–275
  36. Loprinzi CL. Management of cancer anorexia/cachexia. Support Care Cancer. 1995;3:120–122
  37. Von Roenn JH, Knopf K. Anorexia/cachexia in patients with HIV: Lessons for the oncologist. Oncology (Huntingt). 1996;10:1049–1056discussion 62–64, 67–68
  38. Chang AY. Megestrol acetate as a biomodulator. Semin Oncol. 1998;25(2 Suppl 6):58–61
  39. Loprinzi CL, Jensen MD, Jiang NS, Schaid DJ. Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clin Proc. 1992;67:1160–1162
  40. Kontula K, Paavonen T, Luukkainen T, Andersson LC. Binding of progestins to the glucocorticoid receptor (Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes). Biochem Pharmacol. 1983;32:1511–1518
  41. Meacham LR, Mazewski C, Krawiecki N. Mechanism of transient adrenal insufficiency with megestrol acetate treatment of cachexia in children with cancer. J Pediatr Hematol Oncol. 2003;25:414–417
  42. Gomez F, De Kloet ER, Armario A. Glucocorticoid negative feedback on the HPA axis in five inbred rat strains. Am J Physiol. 1998;274(2 Pt 2):R420–R427
  43. Poulin R, Baker D, Poirier D, Labrie F. Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75–1 human breast cancer cells. Breast Cancer Res Treat. 1989;13:161–172
  44. Poulin R, Baker D, Poirier D, Labrie F. Multiple actions of synthetic ‘progestins’ on the growth of ZR-75–1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids. Breast Cancer Res Treat. 1991;17:197–210
  45. Labrie C, Cusan L, Plante M, Lapointe S, Labrie F. Analysis of the androgenic activity of synthetic “progestins” currently used for the treatment of prostate cancer. J Steroid Biochem. 1987;28:379–384
  46. Labrie C, Simard J, Zhao HF, Pelletier G, Labrie F. Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate. Mol Cell Endocrinol. 1990;68:169–179
  47. Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med. 1994;121:393–399
  48. Oster MH, Enders SR, Samuels SJ, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med. 1994;121:400–408
  49. Loprinzi CL, Bernath AM, Schaid DJ, et al. Phase III evaluation of 4 doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Oncology. 1994;51(Suppl 1):2–7
  50. Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol. 2004;22:2469–2476
  51. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central Cancer Treatment Group study. J Clin Oncol. 2002;20:567–573
  52. Karcic E, Philpot C, Morley JE. Treating malnutrition with megestrol acetate: literature review and review of our experience. J Nutr Health Aging. 2002;6:191–200
  53. Simmons SF, Walker KA, Osterweil D. The effect of megestrol acetate on oral food and fluid intake in nursing home residents: A pilot study. J Am Med Dir Assoc. 2005;6(3 Suppl):S5–S11
  54. Yeh S, Wu SY, Levine DM, et al. Quality of life and stimulation of weight gain after treatment with megestrol acetate: Correlation between cytokine levels and nutritional status, appetite in geriatric patients with wasting syndrome. J Nutr Health Aging. 2000;4:246–251
  55. Yeh SS, Wu SY, Lee TP, et al. Improvement in quality-of-life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double-blind, placebo-controlled study. J Am Geriatr Soc. 2000;48:485–492
  56. Femia RA, Goyette RE. The science of megestrol acetate delivery: potential to improve outcomes in cachexia. BioDrugs. 2005;19:179–187
  57. Pascual Lopez A, Roque i Figuls M, Urrutia Cuchi G, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage. 2004;27:360–369
  58. Reuben DB, Hirsch SH, Zhou K, Greendale GA. The effects of megestrol acetate suspension for elderly patients with reduced appetite after hospitalization: A Phase II randomized clinical trial. J Am Geriatr Soc. 2005;53:970–975
  59. McKone EF, Tonelli MR, Aitken ML. Adrenal insufficiency and testicular failure secondary to megestrol acetate therapy in a patient with cystic fibrosis. Pediatr Pulmonol. 2002;34:381–383
  60. Pimentel G, Santos E, Arastu M, Cowan JA. Hyperglycemia in an AIDS patient taking megestrol. Hosp Pract (Off Ed). 1996;31:27–28
  61. Hervas R, Cepeda C, Pulido F. [Cushing syndrome secondary to megestrol acetate in a patient with AIDS]. Med Clin (Barc). 2004;122:638–639
  62. Kropsky B, Shi Y, Cherniack EP. Incidence of deep-venous thrombosis in nursing home residents using megestrol acetate. J Am Med Dir Assoc. 2003;4:255–256
  63. Bennett RG. Megestrol complications. Chest. 2003;123:309–310author reply 10
  64. Naing KK, Dewar JA, Leese GP. Megestrol acetate therapy and secondary adrenal suppression. Cancer. 1999;86:1044–1049
  65. Gonzalez Del Valle L, Herrero Ambrosio A, Martinez Hernandez P, Garcia Diaz B, Jimenez Caballero E. Hyperglycemia induced by megestrol acetate in a patient with AIDS. Ann Pharmacother. 1996;30:1113–1114
  66. van Veelen H, Willemse PH, Sleijfer DT, van der Ploeg E, Sluiter WJ, Doorenbos H. Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients. Cancer Chemother Pharmacol. 1985;15:167–170
  67. Loprinzi CL, Fonseca R, Jensen MD. Megestrol acetate-induced adrenal suppression. J Clin Oncol. 1996;14:689
  68. Lambert CP, Sullivan DH, Freeling SA, Lindquist DM, Evans WJ. Effects of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: a randomized controlled trial. J Clin Endocrinol Metab. 2002;87:2100–2106
  69. Sullivan DH, Roberson PK, Smith ES, Price JA, Bopp MM. Effects of muscle strength training and megestrol acetate on strength, muscle mass, and function in frail older people. J Am Geriatr Soc. 2007;55:20–28
  70. Ibanez J, Izquierdo M, Arguelles I, et al. Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care. 2005;28:662–667
  71. Binder EF, Yarasheski KE, Steger-May K, et al. Effects of progressive resistance training on body composition in frail older adults: results of a randomized, controlled trial. J Gerontol A Biol Sci Med Sci. 2005;60:1425–1431
  72. Izquierdo M, Hakkinen K, Ibanez J, et al. Effects of strength training on submaximal and maximal endurance performance capacity in middle-aged and older men. J Strength Cond Res. 2003;17:129–139
  73. Agin D, Gallagher D, Wang J, Heymsfield SB, Pierson RN, Kotler DP. Effects of whey protein and resistance exercise on body cell mass, muscle strength, and quality of life in women with HIV. AIDS. 2001;15:2431–2440
  74. Evans WJ. Reversing sarcopenia: How weight training can build strength and vitality. Geriatrics. 1996;51:46–4751–53; quiz 4
  75. Fielding RA. The role of progressive resistance training and nutrition in the preservation of lean body mass in the elderly. J Am Coll Nutr. 1995;14:587–594
  76. Gorter RW. Cancer cachexia and cannabinoids. Forsch Komplementarmed. 1999;6(Suppl 3):21–22
  77. Gorter R. Cannabis and cannabidiol: Interview with Robert Gorter, MD (Interview by Fred Gardner). AIDS Treat News. 1998;4–6(No 305): concl.
  78. Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia. 2003;41:161–168
  79. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 1997;12:913–919
  80. Morley JE. Orexigenic and anabolic agents. Clin Geriatr Med. 2002;18:853–866
  81. Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage. 1997;14:7–14
  82. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995;10:89–97
  83. Beal JA. Appetite effect of dronabinol. J Clin Oncol. 1994;12:1524–1525
  84. Struwe M, Kaempfer SH, Geiger CJ, et al. Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother. 1993;27:827–831
  85. Bhasin S, Calof OM, Storer TW, et al. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab. 2006;2:146–159
  86. Batterham MJ, Garsia R. A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. Int J Androl. 2001;24:232–240
  87. Frisoli A, Chaves PH, Pinheiro MM, Szejnfeld VL. The effect of nandrolone decanoate on bone mineral density, muscle mass, and hemoglobin levels in elderly women with osteoporosis: A double-blind, randomized, placebo-controlled clinical trial. J Gerontol A Biol Sci Med Sci. 2005;60:648–653
  88. Schols AM, Soeters PB, Mostert R, Pluymers RJ, Wouters EF. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease (A placebo-controlled randomized trial). Am J Respir Crit Care Med. 1995;152:1268–1274
  89. Gaughan WJ, Liss KA, Dunn SR, et al. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis. 1997;30:495–500
  90. Romeyn M, Gunn N. Resistance exercise and oxandrolone for men with HIV-related weight loss. JAMA. 2000;284:176;author reply 7
  91. Yeh SS, DeGuzman B, Kramer T. Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest. 2002;122:421–428
  92. Berger JR. Resistance exercise and oxandrolone for men with HIV-related weight loss. JAMA. 2000;284:176;author reply 7.
  93. Mwamburi DM, Gerrior J, Wilson IB, et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months. Clin Infect Dis. 2004;38:895–902
  94. Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs. 2004;64:725–750
  95. Collins N. Protein-energy malnutrition and involuntary weight loss: nutritional and pharmacological strategies to enhance wound healing. Expert Opin Pharmacother. 2003;4:1121–1140
  96. Earthman CP, Reid PM, Harper IT, Ravussin E, Howell WH. Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone. JPEN J Parenter Enteral Nutr. 2002;26:357–365
  97. Demling R, De Santi L. Closure of the “non-healing wound” corresponds with correction of weight loss using the anabolic agent oxandrolone. Ostomy Wound Manage. 1998;44:58–624, 6 passim
  98. Spungen AM, Koehler KM, Modeste-Duncan R, Rasul M, Cytryn AS, Bauman WA. 9 clinical cases of nonhealing pressure ulcers in patients with spinal cord injury treated with an anabolic agent: a therapeutic trial. Adv Skin Wound Care. 2001;14:139–144
  99. Mikulin L. Nutrition and its role in wound healing. Ostomy Wound Manage. 2001;47:17–20
  100. Cioroiu M, Hanan SH. Adjuvant anabolic agents: A case report on the successful use of oxandrolone in an HIV-positive patient with chronic stasis ulceration. J Wound Ostomy Continence Nurs. 2001;28:215–218
  101. Krasner DL, Belcher AE. Oxandrolone restores appetite (An increase in weight helps heal wounds). Am J Nurs. 2000;100:53
  102. Demling RH. Oxandrolone, an anabolic steroid, enhances the healing of a cutaneous wound in the rat. Wound Repair Regen. 2000;8:97–102
  103. Demling RH, Orgill DP. The anticatabolic and wound healing effects of the testosterone analog oxandrolone after severe burn injury. J Crit Care. 2000;15:12–17
  104. Demling RH. Comparison of the anabolic effects and complications of human growth hormone and the testosterone analog, oxandrolone, after severe burn injury. Burns. 1999;25:215–221
  105. Erlinger S. Drug-induced cholestasis. J Hepatol. 1997;26(Suppl 1):1–4
  106. Simon DM, Krause R, Galambos JT. Peliosis hepatis in a patient with marasmus. Gastroenterology. 1988;95:805–809
  107. Young GP, Bhathal PS, Sullivan JR, Wall AJ, Fone DJ, Hurley TH. Fatal hepatic coma complicating oxymetholone therapy in multiple myeloma. Aust N Z J Med. 1977;7:47–51
  108. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34:513–554
  109. Payne JR, Kotwinski PJ, Montgomery HE. Cardiac effects of anabolic steroids. Heart. 2004;90:473–475
  110. Sinha-Hikim I, Taylor WE, Gonzalez-Cadavid NF, Zheng W, Bhasin S. Androgen receptor in human skeletal muscle and cultured muscle satellite cells: Up-regulation by androgen treatment. J Clin Endocrinol Metab. 2004;89:5245–5255
  111. Grinspoon S, Corcoran C, Parlman K, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting (A randomized, controlled trial). Ann Intern Med. 2000;133:348–355
  112. Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005;90:678–688
  113. Dolan S, Wilkie S, Aliabadi N, et al. Effects of testosterone administration in human immunodeficiency virus-infected women with low weight: A randomized placebo-controlled study. Arch Intern Med. 2004;164:897–904
  114. Morley JE, Perry HM, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: A preliminary study. J Am Geriatr Soc. 1993;41:149–152
  115. Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: A 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82:1661–1667
  116. Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90:1502–1510
  117. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis. Clin Endocrinol (Oxf). 2005;63:280–293
  118. Miner JN, Chang W, Chapman MS, et al. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007;148:363–373
  119. Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl. 2006;27:135–137
  120. Svanberg E, Ohlsson C, Kimball SR, Lundholm K. rhIGF-I/IGFBP-3 complex, but not free rhIGF-I, supports muscle protein biosynthesis in rats during semistarvation. Eur J Clin Invest. 2000;30:438–446
  121. Schambelan M, Mulligan K, Grunfeld C, et al. Serostim Study Group Recombinant human growth hormone in patients with HIV-associated wasting (A randomized, placebo-controlled trial). Ann Intern Med. 1996;125:873–882
  122. Tai VW, Schambelan M, Algren H, Shayevich C, Mulligan K. Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting. Clin Infect Dis. 2002;35:1258–1262
  123. Cominelli S, Raguso CA, Karsegard L, et al. Weight-losing HIV-infected patients on recombinant human growth hormone for 12 wk: A national study. Nutrition. 2002;18:583–586
  124. Waters D, Danska J, Hardy K, et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting (A randomized, double-blind, placebo-controlled trial). Ann Intern Med. 1996;125:865–872
  125. Kaiser FE, Silver AJ, Morley JE. The effect of recombinant human growth hormone on malnourished older individuals. J Am Geriatr Soc. 1991;39:235–240
  126. Hedstrom M, Saaf M, Brosjo E, et al. Positive effects of short-term growth hormone treatment on lean body mass and BMC after a hip fracture: A double-blind placebo-controlled pilot study in 20 patients. Acta Orthop Scand. 2004;75:394–401
  127. Grunfield C, Papadakis M. Growth hormone research and therapy. Science. 1997;275:465
  128. Papadakis MA, Grady D, Black D, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med. 1996;124:708–716
  129. Chu LW, Lam KS, Tam SC, et al. A randomized controlled trial of low-dose recombinant human growth hormone in the treatment of malnourished elderly medical patients. J Clin Endocrinol Metab. 2001;86:1913–1920
  130. Zhang X, Wang Y, Li Z, et al. [Applied study on small-dose growth hormone supplement for aging-related symptom complex]. Zhonghua Nan Ke Xue. 2004;10:601–6037
  131. Biolo G, Iscra F, Bosutti A, et al. Growth hormone decreases muscle glutamine production and stimulates protein synthesis in hypercatabolic patients. Am J Physiol Endocrinol Metab. 2000;279:E323–E332
  132. Pawlikowska-Haddal A, Cohen P. Advances in pediatric growth hormone therapy: IGF-I-based dosing. Indian Pediatr. 2006;43:577–581
  133. Bowlby DA, Rapaport R. Safety and efficacy of growth hormone therapy in childhood. Pediatr Endocrinol Rev. 2004;2(Suppl 1):68–77
  134. Feldt-Rasmussen U, Wilton P, Jonsson P. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults. Growth Horm IGF Res. 2004;14(Suppl A):S51–S58
  135. Greenlund LJ, Nair KS. Sarcopenia—consequences, mechanisms, and potential therapies. Mech Ageing Dev. 2003;124:287–299
  136. Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Curr Opin Clin Nutr Metab Care. 2004;7:405–410
  137. Burgos Pelaez R. [Global therapeutic approach to sarcopenia]. Nutr Hosp. 2006;21(Suppl 3):51–60
  138. Borst SE. Interventions for sarcopenia and muscle weakness in older people. Age Ageing. 2004;33:548–555
  139. Asakawa A, Inui A, Kaga T, et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology. 2001;120:337–345
  140. Peino R, Baldelli R, Rodriguez-Garcia J, et al. Ghrelin-induced growth hormone secretion in humans. Eur J Endocrinol. 2000;143:R11–R14
  141. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:2832–2836
  142. Lainscak M, Andreas S, Scanlon PD, Somers VK, Anker SD. Ghrelin and neurohumoral antagonists in the treatment of cachexia associated with cardiopulmonary disease. Intern Med. 2006;45:837
  143. Nagaya N, Kojima M, Kangawa K. Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia. Intern Med. 2006;45:127–134
  144. Strassburg S, Anker SD. Metabolic and immunologic derangements in cardiac cachexia: Where to from here?. Heart Fail Rev. 2006;11:57–64
  145. Akashi YJ, Springer J, Anker SD. Cachexia in chronic heart failure: Prognostic implications and novel therapeutic approaches. Curr Heart Fail Rep. 2005;2:198–203
  146. Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest. 2005;128:1187–1193
  147. Janssen JA, van der Lely AJ, Lamberts SW. Is there a role of ghrelin in preventing catabolism?. J Endocrinol Invest. 2004;27:400–403
  148. Sullivan DH. The role of nutrition in increased morbidity and mortality. Clin Geriatr Med. 1995;11:661–674
  149. Sullivan DH. Risk factors for early hospital readmission in a select population of geriatric rehabilitation patients: The significance of nutritional status. J Am Geriatr Soc. 1992;40:792–798
  150. Sullivan DH, Bopp MM, Roberson PK. Protein-energy undernutrition and life-threatening complications among the hospitalized elderly. J Gen Intern Med. 2002;17:923–932
  151. Campbell WW, Trappe TA, Wolfe RR, Evans WJ. The recommended dietary allowance for protein may not be adequate for older people to maintain skeletal muscle. J Gerontol A Biol Sci Med Sci. 2001;56:M373–M380
  152. Brodsky IG, Suzara D, Hornberger TA, et al. Isoenergetic dietary protein restriction decreases myosin heavy chain IIx fraction and myosin heavy chain production in humans. J Nutr. 2004;134:328–334
  153. Evans WJ. Protein nutrition, exercise and aging. J Am Coll Nutr. 2004;23(6 Suppl):601S–609S
  154. Collins N. Arginine and wound healing. Adv Skin Wound Care. 2001;14:16–17
  155. Potter JM, Roberts MA, McColl JH, Reilly JJ. Protein energy supplements in unwell elderly patients—a randomized controlled trial. JPEN J Parenter Enteral Nutr. 2001;25:323–329
  156. Luiking YC, Poeze M, Ramsay G, Deutz NE. The role of arginine in infection and sepsis. JPEN J Parenter Enteral Nutr. 2005;29(1 Suppl):S70–S74
  157. Singleton KD, Wischmeyer PE. Oral glutamine enhances heat shock protein expression and improves survival following hyperthermia. Shock. 2006;25:295–299
  158. Singleton KD, Beckey VE, Wischmeyer PE. Glutamine prevents activation of NF-kappaB and stress kinase pathways, attenuates inflammatory cytokine release, and prevents acute respiratory distress syndrome (ARDS) following sepsis. Shock. 2005;24:583–589
  159. Kim YS, Kim GY, Kim JH, et al. Glutamine inhibits lipopolysaccharide-induced cytoplasmic phospholipase A2 activation and protects against endotoxin shock in mouse. Shock. 2006;25:290–294
  160. Lin MT, Kung SP, Yeh SL, et al. Glutamine-supplemented total parenteral nutrition attenuates plasma interleukin-6 in surgical patients with lower disease severity. World J Gastroenterol. 2005;11:6197–6201
  161. Furukawa S, Saito H, Inoue T, et al. Supplemental glutamine augments phagocytosis and reactive oxygen intermediate production by neutrophils and monocytes from postoperative patients in vitro. Nutrition. 2000;16:323–329
  162. Austgen TR, Chen MK, Dudrick PS, Copeland EM, Souba WW. Cytokine regulation of intestinal glutamine utilization. Am J Surg. 1992;163:174–179discussion 9–80
  163. Hickson RC, Czerwinski SM, Wegrzyn LE. Glutamine prevents downregulation of myosin heavy chain synthesis and muscle atrophy from glucocorticoids. Am J Physiol. 1995;268:E730–E734
  164. Williams JZ, Abumrad N, Barbul A. Effect of a specialized amino acid mixture on human collagen deposition. Ann Surg. 2002;236:369–374discussion 74–75
  165. Arwert LI, Deijen JB, Drent ML. Effects of an oral mixture containing glycine, glutamine and niacin on memory, GH and IGF-I secretion in middle-aged and elderly subjects. Nutr Neurosci. 2003;6:269–275
  166. Rathmacher JA, Nissen S, Panton L, et al. Supplementation with a combination of beta-hydroxy-beta-methylbutyrate (HMB), arginine, and glutamine is safe and could improve hematological parameters. JPEN J Parenter Enteral Nutr. 2004;28:65–75
  167. May PE, Barber A, D’Olimpio JT, Hourihane A, Abumrad NN. Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am J Surg. 2002;183:471–479
  168. Rieu I, Balage M, Sornet C, et al. Leucine supplementation improves muscle protein synthesis in elderly men independently of hyperaminoacidaemia. J Physiol. 2006;575:305–315
  169. Olsen S, Aagaard P, Kadi F, et al. Creatine supplementation augments the increase in satellite cell and myonuclei number in human skeletal muscle induced by strength training. J Physiol. 2006;573:525–534
  170. Kuethe F, Krack A, Richartz BM, Figulla HR. Creatine supplementation improves muscle strength in patients with congestive heart failure. Pharmazie. 2006;61:218–222
  171. Okudan N, Gokbel H. The effects of creatine supplementation on performance during the repeated bouts of supramaximal exercise. J Sports Med Phys Fitness. 2005;45:507–511
  172. Gutman AB, Yu TF. Hyperglutamatemia in primary gout. Adv Exp Med Biol. 1974;41:395–399
  173. Gutman AB, Yu TF. Hyperglutamatemia in primary gout. Am J Med. 1973;54:713–724
  174. Yu TF, Adler M, Bobrow E, Gutman AB. Plasma and urinary amino acids in primary gout, with special reference to glutamine. J Clin Invest. 1969;48:885–894
  175. Delbarre F. New prospects in the treatment of gouty dyspurinia. Arch Interam Rheumatol. 1964;45:230–253
  176. Zaka R, Williams CJ. New developments in the epidemiology and genetics of gout. Curr Rheumatol Rep. 2006;8:215–223
  177. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8(Suppl 1):S2
  178. Jump DB, Clarke SD, Thelen A, Liimatta M. Coordinate regulation of glycolytic and lipogenic gene expression by polyunsaturated fatty acids. J Lipid Res. 1994;35:1076–1084
  179. Ishii S, Iizuka K, Miller BC, Uyeda K. Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc Natl Acad Sci U S A. 2004;101:15597–15602
  180. Dentin R, Benhamed F, Pegorier JP, et al. Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation. J Clin Invest. 2005;115:2843–2854
  181. Mishra A, Chaudhary A, Sethi S. Oxidized omega-3 fatty acids inhibit NF-kappaB activation via a PPARalpha-dependent pathway. Arterioscler Thromb Vasc Biol. 2004;24:1621–1627
  182. Ferrucci L, Cherubini A, Bandinelli S, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab. 2006;91:439–446
  183. Tisdale MJ, Dhesi JK. Inhibition of weight loss by omega-3 fatty acids in an experimental cachexia model. Cancer Res. 1990;50:5022–5026
  184. Fearon KC, Von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A randomised double blind trial. Gut. 2003;52:1479–1486
  185. Costelli P, Llovera M, Lopez-Soriano J, et al. Lack of effect of eicosapentaenoic acid in preventing cancer cachexia and inhibiting tumor growth. Cancer Lett. 1995;97:25–32
  186. Donnelly SM, Ali MA, Churchill DN. Effect of n-3 fatty acids from fish oil on hemostasis, blood pressure, and lipid profile of dialysis patients. J Am Soc Nephrol. 1992;2:1634–1639
  187. Richard MJ, Sirajeddine MK, Cordonnier D, et al. Relationship of omega-3 fatty acid supplementation to plasma lipid peroxidation in predialysis patients with hypertriglyceridaemia. Eur J Med. 1993;2:15–188
  188. Bartoli GM, Palozza P, Luberto C, Franceschelli P, Piccioni E. Dietary fish oil inhibits human erythrocyte Mg,NaK-ATPase. Biochem Biophys Res Commun. 1995;213:881–887
  189. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer. 1990;65:2657–2662
  190. Steinpreis RE, Kaczmarek HJ, Harrington A. The effects of cyproheptadine on vacuous jaw movements in rats: A comparison with haloperidol and clozapine. Psychopharmacol Bull. 1996;32:129–134
  191. Hyltander A, Daneryd P, Sandstrom R, Korner U, Lundholm K. Beta-adrenoceptor activity and resting energy metabolism in weight losing cancer patients. Eur J Cancer. 2000;36:330–334
  192. Lamont LS, Brown T, Riebe D, Caldwell M. The major components of human energy balance during chronic beta-adrenergic blockade. J Cardiopulm Rehabil. 2000;20:247–250
  193. Reichel K, Rehfeldt C, Weikard R, Schadereit R, Krawielitzki K. [Effect of a beta-agonist and a beta-agonist/beta-antagonist combination on muscle growth, body composition and protein metabolism in rats]. Arch Tierernahr. 1993;45:211–225
  194. Hryniewicz K, Androne AS, Hudaihed A, Katz SD. Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure. J Card Fail. 2003;9:464–468
  195. Hopson JR, Rea RF, Kienzle MG. Alterations in reflex function contributing to syncope: orthostatic hypotension, carotid sinus hypersensitivity and drug-induced dysfunction. Herz. 1993;18:164–174
  196. Mills TA, Kawji MM, Cataldo VD, et al. Profound sinus bradycardia due to diltiazem, verapamil, and/or beta-adrenergic blocking drugs. J La State Med Soc. 2004;156:327–331
  197. Gambardella A, Tortoriello R, Pesce L, Tagliamonte MR, Paolisso G, Varricchio M. Intralipid infusion combined with propranolol administration has favorable metabolic effects in elderly malnourished cancer patients. Metabolism. 1999;48:291–297
  198. Anker SD, Cicoira M. [Chronic heart failure and cardiac cachexia and links between the endocrine and immune systems]. Z Kardiol. 1999;88(Suppl 3):S18–S23
  199. von Haehling S, Sandek A, Anker SD. Pleiotropic effects of angiotensin-converting enzyme inhibitors and the future of cachexia therapy. J Am Geriatr Soc. 2005;53:2030–2031
  200. Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet. 2003;361:1077–1083
  201. Adigun AQ, Ajayi AA. The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia. Eur J Heart Fail. 2001;3:359–363
  202. Springer J, Filippatos G, Akashi YJ, Anker SD. Prognosis and therapy approaches of cardiac cachexia. Curr Opin Cardiol. 2006;21:229–233
  203. Maggio M, Ceda GP, Lauretani F, et al. Relation of angiotensin-converting enzyme inhibitor treatment to insulin-like growth factor-1 serum levels in subjects >65 years of age (the InCHIANTI study). Am J Cardiol. 2006;97:1525–1529
  204. Cheung BM. Blockade of the renin-angiotensin system. Hong Kong Med J. 2002;8:185–191
  205. Ionescu SD, Sandru V, Leuciuc E, et al. [Undesirable effects and interaction to angiotensin converting enzyme inhibitors therapy]. Rev Med Chir Soc Med Nat Iasi. 2002;106:128–131
  206. Roubenoff R, Parise H, Payette HA, et al. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med. 2003;115:429–435
  207. Daynes RA, Araneo BA, Ershler WB, Maloney C, Li GZ, Ryu SY. Altered regulation of IL-6 production with normal aging (Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative). J Immunol. 1993;150:5219–5230
  208. Ershler WB. Interleukin-6: A cytokine for gerontologists. J Am Geriatr Soc. 1993;41:176–181
  209. Ershler WB, Sun WH, Binkley N, et al. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res. 1993;12:225–230
  210. Kania DM, Binkley N, Checovich M, Havighurst T, Schilling M, Ershler WB. Elevated plasma levels of interleukin-6 in postmenopausal women do not correlate with bone density. J Am Geriatr Soc. 1995;43:236–239
  211. Ershler WB, Sun WH, Binkley N. The role of interleukin-6 in certain age-related diseases. Drugs Aging. 1994;5:358–365
  212. Zhang J, Dai J, Lu Y, et al. In vivo visualization of aging-associated gene transcription: Evidence for free radical theory of aging. Exp Gerontol. 2004;39:239–247
  213. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51:245–270
  214. Meyer KC, Ershler W, Rosenthal NS, Lu XG, Peterson K. Immune dysregulation in the aging human lung. Am J Respir Crit Care Med. 1996;153:1072–1079
  215. Saini A, Nasser AS, Stewart CE. Waste management—cytokines, growth factors and cachexia. Cytokine Growth Factor Rev. 2006;17:475–486
  216. Zhang J, Stirling B, Temmerman ST, et al. Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J Clin Invest. 2006;116:3042–3049
  217. Gilson H, Schakman O, Combaret L, et al. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology. 2007;148:452–460
  218. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506–512
  219. Reuben DB, Cheh AI, Harris TB, et al. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc. 2002;50:638–644
  220. Cappola AR, Xue QL, Ferrucci L, Guralnik JM, Volpato S, Fried LP. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab. 2003;88:2019–2025
  221. Volpato S, Guralnik JM, Ferrucci L, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women’s health and aging study. Circulation. 2001;103:947–953
  222. Haslett PA. Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol. 1998;25(2 Suppl 6):53–57
  223. Grunfeld C. The wasting syndrome in AIDS: Mechanisms and implications. Nutrition. 1998;14:867–868
  224. Yeh SS, Schuster MW. Geriatric cachexia: The role of cytokines. Am J Clin Nutr. 1999;70:183–197
  225. Balkwill F, Coussens LM. Cancer: An inflammatory link. Nature. 2004;431:405–406
  226. Figueras M, Busquets S, Carbo N, Almendro V, Argiles JM, Lopez-Soriano FJ. Cancer cachexia results in an increase in TNF-alpha receptor gene expression in both skeletal muscle and adipose tissue. Int J Oncol. 2005;27:855–860
  227. Morley JE, Baumgartner RN. Cytokine-related aging process. J Gerontol A Biol Sci Med Sci. 2004;59:M924–M929
  228. Maggio M, Guralnik JM, Longo DL, Ferrucci L. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci. 2006;61:575–584
  229. Roth SM, Metter EJ, Ling S, Ferrucci L. Inflammatory factors in age-related muscle wasting. Curr Opin Rheumatol. 2006;18:625–630
  230. Di Iorio A, Ferrucci L, Sparvieri E, et al. Serum IL-1beta levels in health and disease: A population-based study (‘The InCHIANTI study.’). Cytokine. 2003;22:198–205
  231. Morley JE, Thomas DR, Wilson MM. Cachexia: Pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83:735–743
  232. Keller ET, Chang C, Ershler WB. Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biol Chem. 1996;271:26267–26275
  233. Yasumoto K, Mukaida N, Harada A, et al. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res. 1995;55:921–927
  234. Fujimoto-Ouchi K, Tamura S, Mori K, Tanaka Y, Ishitsuka H. Establishment and characterization of cachexia-inducing and -non-inducing clones of murine colon 26 carcinoma. Int J Cancer. 1995;61:522–528
  235. Strassmann G, Kambayashi T. Inhibition of experimental cancer cachexia by anti-cytokine and anti-cytokine-receptor therapy. Cytokines Mol Ther. 1995;1:107–113
  236. Ferrucci L, Penninx BW, Volpato S, et al. Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. J Am Geriatr Soc. 2002;50:1947–1954
  237. Barbieri M, Ferrucci L, Ragno E, et al. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am J Physiol Endocrinol Metab. 2003;284:E481–E487
  238. Taaffe DR, Harris TB, Ferrucci L, Rowe J, Seeman TE. Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. J Gerontol A Biol Sci Med Sci. 2000;55:M709–M715
  239. Ferrucci L, Harris TB, Guralnik JM, et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc. 1999;47:639–646
  240. Elosua R, Bartali B, Ordovas JM, Corsi AM, Lauretani F, Ferrucci L. Association between physical activity, physical performance, and inflammatory biomarkers in an elderly population: The InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2005;60:760–767
  241. Reuben DB, Ferrucci L, Wallace R, et al. The prognostic value of serum albumin in healthy older persons with low and high serum interleukin-6 (IL-6) levels. J Am Geriatr Soc. 2000;48:1404–1407
  242. Grunfeld C, Feingold KR. Tumor necrosis factor, interleukin, and interferon induced changes in lipid metabolism as part of host defense. Proc Soc Exp Biol Med. 1992;200:224–227
  243. Grunfeld C, Feingold KR. The role of the cytokines, interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDS. J Nutr. 1992;122(3 Suppl):749–753
  244. Llovera M, Carbo N, Garcia-Martinez C, et al. Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats. Biochem Biophys Res Commun. 1996;221:653–655
  245. Truyens C, Torrico F, Angelo-Barrios A, et al. The cachexia associated with Trypanosoma cruzi acute infection in mice is attenuated by anti-TNF-alpha, but not by anti-IL-6 or anti-IFN-gamma antibodies. Parasite Immunol. 1995;17:561–568
  246. Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr. 2006;84:1463–1472
  247. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? (The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH). Int J Cardiol. 2002;86:123–130
  248. Mantovani G, Maccio A, Esu S, et al. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer. 1997;33:602–607
  249. Sany J. [Monoclonal antibodies in the treatment of rheumatoid arthritis: toward a therapeutic revolution]. C R Biol. 2006;329:228–240
  250. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–2285
  251. Thomas JE, Taoka CR, Gibbs BT, Fraser SL. Fatal pulmonary Mycobacterium abscessus infection in a patient using etanercept. Hawaii Med J. 2006;65:12–15
  252. Fitch PG, Cron RQ. Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-alpha. J Rheumatol. 2006;33:825;author reply 6–7
  253. Goldberg RM, Loprinzi CL, Mailliard JA, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? (A randomized, double-blind, placebo-controlled trial). J Clin Oncol. 1995;13:2856–2859
  254. Landman D, Sarai A, Sathe SS. Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study. Clin Infect Dis. 1994;18:97–99
  255. Kruse A, Rieneck K, Kappel M, et al. Pentoxifylline therapy in HIV seropositive subjects with elevated TNF. Immunopharmacology. 1995;31:85–91
  256. Jackson AJ, Schumacher HJ. The teratogenic activity of a thalidomide analogus EM12 in rats on a low-zinc diet. Teratology. 1979;19:341–344
  257. Jackson R. The fetus: Medicine’s newest patient. J Ir Med Assoc. 1973;66:219–221
  258. Sathe SS, Tsigler D, Sarai A, Kumar P. Pentoxifylline impairs macrophage defense against Mycobacterium avium complex. J Infect Dis. 1995;172:863–866
  259. Sathe SS, Sarai A, Tsigler D, Nedunchezian D. Pentoxifylline aggravates impairment in tumor necrosis factor-alpha secretion and increases mycobacterial load in macrophages from AIDS patients with disseminated Mycobacterium avium-intracellulare complex infection. J Infect Dis. 1994;170:484–487

PII: S1525-8610(07)00253-8

doi: 10.1016/j.jamda.2007.05.001

JAMDA
Volume 8, Issue 6 , Pages 363-377 , July 2007

Article Tools

* Image Usage & Resolution